Guggenheim Assumes CRISPR Therapeutics at Neutral
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Debjit Chattopadhyay has assumed coverage of CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral rating.
June 28, 2024 | 11:56 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Guggenheim analyst Debjit Chattopadhyay has assumed coverage of CRISPR Therapeutics with a Neutral rating, indicating a balanced view on the stock's potential.
The Neutral rating suggests that the analyst sees neither strong upside nor downside potential in the short term. This balanced view may lead to limited immediate impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100